Semax / selank stack: what's in it
- 2 sources
- How we source
- We don't sell peptides. We never link "research use only" sellers.
The parts
Regulatory status by component
Not FDA-approved How we label status
- As of October 4, 2026, Semax is not FDA-approved. On July 24, 2026, FDA's compounding advisory committee voted to recommend adding it to the 503A bulks list; FDA staff had recommended against it. FDA has not proposed that change. See Semax in the Index →
- As of October 4, 2026, Selank is not FDA-approved for any use and is not on FDA's 503A bulks list. See Selank in the Index →
Status as of October 4, 2026
- As a combination
- No category as a combination (see components)
Timeline
Scroll sideways to see all columns.
Timeline table
| Date | What happened | Source |
|---|---|---|
| FDA warning letter to a compounding clinic states that Selank and Semax were not nominated for inclusion on the 503A bulks list. | FDA, event of November 10, 2021, on fda.gov | |
| FDA lists semax (heptapeptide) and selank acetate (TP-7) among bulk drug substances nominated but withdrawn (previously in category 2, withdrawn by the nominators) on its page of bulk drug substances that may present significant safety risks in compounding (content current as of 2026-04-22). | FDA, event of April 22, 2026, on fda.gov | |
| FDA presentation for the July 24, 2026 Pharmacy Compounding Advisory Committee meeting states semax products are marketed online alone and in combination with selank. | FDA, event of July 24, 2026, on fda.gov |
Get updates on Semax / selank stack
The research on Semax / selank stack
Key facts
Also known as: semax selank, semax selank stack, russian nootropic stack, russian stack
- Parts
- Semax and Selank
- Route
- nasal
References
Status sources
Sources as of October 4, 2026
What this doesn’t establish
Results for one compound don't tell you what the two do together.